RxDoctor Payments Data

Alysha Chandran, NP

Family · Seneca, SCNPI 1316320278

Payments from drug & device makers

$1,412in general payments, 2019–2025

Across 72 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$489
  • GSK$272
  • Insmed, Inc.$163
  • Sanofi$117
  • Harmony Biosciences LLC$77
  • AstraZeneca$70
  • plus $224 from 7 others

What the payments were for

  • Food & beverage$1,39399%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,412 in reported general payments places this provider in the 70th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$16,718
Medicare patients
228
Services billed
257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan13$161,080
Trelegy ElliptaFluticasone/Umeclidin/Vilanter126$125,078
Breo ElliptaFluticasone/Vilanterol95$54,434
XolairOmalizumab17$43,918
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$23,705
Spiriva RespimatTiotropium Bromide38$21,312
Stiolto RespimatTiotropium Br/Olodaterol Hcl44$20,337
EliquisApixaban19$19,599
Combivent RespimatIpratropium/Albuterol Sulfate16$14,022
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$10,193
Advair HfaFluticasone Propion/Salmeterol22$8,042
Albuterol Sulfate HfaAlbuterol Sulfate220$7,198
DuleraMometasone/Formoterol18$6,070
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$5,647
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$4,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$272$189,706232 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$489$55,67198 claims
AstraZenecaBreztri Aerosphere$70$23,70536 claims
PfizerEliquis$13$19,59919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,248 family providers in South Carolina.

Other family in Seneca

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →